BioTime, Inc. BTX today announced that it has entered into an
exclusive license agreement with the University of California, Los Angeles
(UCLA) for novel technology related to the treatment of stroke. The licensed
technology, developed in the laboratories of Tom Carmichael, MD, PhD of UCLA's
Department of Neurology, at the David Geffen School of Medicine, uses one of
BioTime's HyStem^® hydrogels to deliver locally released growth factors to
improve recovery from stroke. Pre-clinical studies have demonstrated that the
localized delivery of growth factors such as brain-derived neurotrophic factor
(BDNF) results in a statistically significant improvement in post-stroke motor
function in a murine model of ischemic stroke.
Concurrent with the execution of this exclusive license agreement, BioTime has
entered into a Sponsored Research Agreement with UCLA to support on-going
pre-clinical work in Dr. Carmichael's laboratory to advance the understanding
of this technology and develop data in support for the potential filing of an
Investigational New Drug Application (IND) for human clinical trails.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in